Neoadjuvant Radiation with Concurrent 5-FU Resulting in Complete Pathologic Response in Stage IIIB Squamous Cell Carcinoma of the Urethra

Krishna H Suthar; Meghana Kesireddy; Mark Sides; Amit Correa; Aijan Ukudeyva; Rohit Venkatesan

doi:10.1155/2020/7948538

Neoadjuvant Radiation with Concurrent 5-FU Resulting in Complete Pathologic Response in Stage IIIB Squamous Cell Carcinoma of the Urethra

Case Rep Oncol Med. 2020 Feb 14:2020:7948538. doi: 10.1155/2020/7948538. eCollection 2020.

Authors

Krishna H Suthar¹, Meghana Kesireddy¹, Mark Sides², Amit Correa², Aijan Ukudeyva³, Rohit Venkatesan⁴

Affiliations

¹ Department of Internal Medicine, University of Texas Medical Branch, USA.
² Department of Internal Medicine, Division of Hematology and Medical Oncology, University of Texas Medical Branch, USA.
³ Department of Pathology, University of Texas Medical Branch, USA.
⁴ Division of Medical Oncology, MD Anderson Cancer Center, USA.

Abstract

Squamous cell carcinoma (SCC) of the urethra is a rare malignancy, comprising less than 1% of all malignancies. The annual age-adjusted incidence of urethral SCC is 4.3 per million in men and 1.5 per million in women. Due to the rarity of the disease, there are a limited number of prospective randomized controlled trials to evaluate the optimal management of locally advanced urethral SCC. Here, we present the case of a 47-year-old man with stage IIIB urethral squamous cell cancer that showed complete clinical and pathologic response to neoadjuvant chemoradiation with only 5-flurouracil after incomplete response to traditional chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP).

Publication types

Case Reports